FDA‑approved CDMO providing end-to-end solid-dosage development, clinical and commercial manufacturing and packaging, including handling of highly toxic APIs (safe‑bridge level 4). Targets pharmaceutical sponsors and drug developers with cGMP operations, robust quality assurance and validation, focused on reducing costs and lead times while upholding high pharmaceutical manufacturing standards.